Abstract
Get full access to this article
View all access options for this article.
References
1.
Rigby R.J.
,
Hawley C.M.
Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998 ; 13 : 154 –9 .
2.
Nakamoto H.
Encapsulating peritoneal sclerosis—a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005 ; 25 (Suppl 4 ): S30 –8 .
3.
Lafrance J.P.
,
Létourneau I.
,
Ouimet D.
,
Bonnardeaux A.
,
Leblanc M.
,
Mathieu N.
Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 2008 ; 51 : e7 –10 .
4.
Bozkurt D.
,
Cetin P.
,
Sipahi S.
,
Hur E.
,
Nar H.
,
Ertilav M.
The effects of renin–angiotensin system inhibition on regression of encapsulating peritoneal sclerosis. Perit Dial Int 2008 ; 28 (Suppl 5 ): S38 –42 .
5.
Guest S.
Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009 ; 29 : 252 –5 .
6.
Kuhn M.A.
,
Wang X.
,
Payne W.G.
,
Ko F.
,
Robson M.C.
Tamoxifen decreases fibroblast function and downregulates TGFβ2 in Dupuytren's affected palmar fascia. J Surg Res 2002 ; 103 : 146 –52 .
7.
Huang J.W.
,
Yen C.J.
,
Wu H.Y.
,
Chiang C.K.
,
Cheng H.T.
,
Lien Y.C.
Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis. Blood Purif 2011 ; 31 : 252 –8 .
8.
Wang X.X.
,
Jiang T.
,
Levi M.
Nuclear hormone receptors in diabetic nephropathy. Nat Rev Nephrol 2010 ; 6 : 342 –51 .
9.
Detti L.
,
Saed G.M.
,
Jiang Z.L.
,
Kruger M.L.
,
Diamond M.P.
The effect of estradiol on the expression of estrogen, progesterone, androgen, and prolactin receptors in human peritoneal fibroblasts. J assist Reprod Genet 2008 ; 25 : 245 –50 .
10.
Krediet R.T.
,
Sampimon D.E.
,
Vlijm A.
,
Coester A.M.
,
Struijk D.G.
,
Smit W.
Biological markers in the peritoneal dialysate effluent: are they useful. Contrib Nephrol 2009 ; 163 : 54 –9 .